MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)

• Status: Completed
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will test the safety and effectiveness of MK0916 in patients with Type 2 Diabetes Mellitus and Metabolic Syndrome.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Have Type 2 Diabetes

• 18 to 65 years of age

Exclusion Criteria:

• History of Type 1 Diabetes Mellitus

• Have been treated with insulin in the past 8 weeks

• On a weight loss program and have ongoing weight loss

• Taking weight loss medication

• Have had surgery requiring general anesthesia in the past 30 days or have a planned surgery

• Have taken another investigational drug in the last 8 weeks

• Have active liver disease

• Have a history of major surgery involving gastric or intestinal bypass